Skip to main content

Medical Device Regulation in India

BayBiotech.NET

At present, the Indian market for medical devices is largely unregulated and Medical devices can freely be imported into India. Solely, the key decision maker is either the doctor, or a private or government hospital that evaluates the device and imports it to India.

Although the FDA approved products are preferred because of their better
quality and performance, but since India is a price sensitive market, low priced, poor quality medical devices find a bigger and more favored market.

To ensure the quality of healthcare service and keeping the globalization of the clinical trials in mind, the Government of India is in the process of developing regulations for medical devices. A set of guidelines are expected to evolve that would bring a select group of medical devices under the regulatory framework.

In India, the authority regulating medical devices will be the Central Drug Standard Control Organization (CDSCO) in the Ministry of Health. The CDSCO is the authority, which lays down rules, standards and approves import and manufacturing of drugs, diagnostics, devices, and cosmetics. Currently, CDSCO’s functions are to establish the standards and regulations for drugs, blood and blood products, intravenous fluids, and vaccines. With added responsibility of regulating the medical devices industry, CDSCO will be the approving authority for import, manufacture and sale of medical devices in India.
To read more on the topic follow the link: http://www.cdsco.nic.in

Reference:

1. http://www.trade.gov/td/health/india_med_registration05.pdf

Comments

Post a Comment

Popular posts from this blog

Good Machine Learning Practices

BayBiotech.NET A joint effort by FDA,  United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) and Health Canada have developed guiding principles to help promote utilization of medical devices that are safe and effective and utilize artiificial intelligence and machine learning. To find out more details check out the link here!
Post a Comment
Read more

Group C (Treatment IND) Drugs

BayBiotech.NET Since 1976, National Cancer Institute (NCI) in agreement with FDA has established the Group C classification system to allow access to certain drugs for the cancer patients specifically falling under a category that adequate alternative therapy or if the available alternative therapy has significant toxic effects. Each Group C drug protocol specifies patient eligibility and drug use information. Group C drugs are provided only to properly trained physicians who have registered themselves with NCI using a special form to assure that their patient qualifies under guidelines - or protocols - for the drug. Physicians using drugs under Group C have no reporting requirements to the NCI other than the obligation to report adverse drug reactions. Group C drugs are provided free of charge, and the Centers for Medicare and Medicaid Services provides coverage for care associated with Group C therapy. Making Group C drugs available to the critically ill patients not only provi...
Post a Comment
Read more

Amendments for High Risk Device Type Regulatory Pathway

BayBiotech.NET Government Accounting Office (“GAO”) has issued a long-awaited report evaluating the use of the 510(k) process by the Food and Drug Administration (“FDA” or the “Agency”) in the January of 2009. Report mainly focused on Preamendment class III devices. Although most high-risk class III medical devices are subject to the demanding premarket approval (“PMA”) process, preamendment class III devices may be cleared through the 510(k) pathway until FDA issues regulations requiring a PMA. Under the Safe Medical Devices Act of 1990, FDA was required either to reclassify preamendment class III devices into class I or II, or (2) issue regulations requiring PMA approval for the devices, GAO noted that 20 preamendment class III device types have not yet been addressed by the Agency. GAO has urged FDA to take required steps to address the remaining class III devices that continue to be eligible for 510(k) review. As a result of the report, FDA has committed to address al...
Post a Comment
Read more